Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for REGENXBIO Inc. (RGNX : NSDQ)

• Company Description    REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. Number of Employees: 372

• Price / Volume Information    Yesterday's Closing Price: $20.67 Daily Weekly Monthly 20 Day Moving Average: 432,470 shares Shares Outstanding: 43.13 (millions) Market Capitalization: $891.58 (millions) Beta: 1.12 52 Week High: $46.46 52 Week Low: $19.07 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -29.79% -23.07% 12 Week -16.04% -8.90% Year To Date -36.79% -24.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9804 MEDICAL CENTER DRIVE - ROCKVILLE,MD 20850 USA ph: 240-552-8181 fax: - ir@regenxbio.com http://www.regenxbio.com

• General Corporate Information    Officers Kenneth T. Mills - President; Chief Executive Officer and Director Allan M. Fox - Chairman of the Board of Directors Vittal Vasista - Chief Financial Officer Daniel J. Abdun-Nabi - Director Jean Bennett - Director Peer Information REGENXBIO Inc. (CORR.) REGENXBIO Inc. (RSPI) REGENXBIO Inc. (CGXP) REGENXBIO Inc. (BGEN) REGENXBIO Inc. (GTBP) REGENXBIO Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 75901B107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 43.13 Most Recent Split Date: (:1) Beta: 1.12 Market Capitalization: $891.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.57 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.47 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 11.81% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 8.91 PEG Ratio: - Price Ratios Price/Book: 1.29 Price/Cash Flow: 6.17 Price / Sales: 1.88 EPS Growth vs. Year Ago Period: -35.00% vs. Previous Quarter: -124.29% Sales Growth vs. Year Ago Period: 17.66% vs. Previous Quarter: -94.43% ROE 03/31/22 - 17.92 12/31/21 - 22.35 09/30/21 - -44.70 ROA 03/31/22 - 11.50 12/31/21 - 14.09 09/30/21 - -26.35 Current Ratio 03/31/22 - 3.73 12/31/21 - 3.98 09/30/21 - 3.84 Quick Ratio 03/31/22 - 3.73 12/31/21 - 3.98 09/30/21 - 3.84 Operating Margin 03/31/22 - 22.91 12/31/21 - 27.18 09/30/21 - -228.08 Net Margin 03/31/22 - 21.38 12/31/21 - 27.18 09/30/21 - -228.08 Pre-Tax Margin 03/31/22 - 24.20 12/31/21 - 30.03 09/30/21 - -221.91 Book Value 03/31/22 - 15.99 12/31/21 - 17.87 09/30/21 - 10.79 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©